HBsAg (-)/HBsAb (-)/HBeAg (-)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy

Shui, LP; Zhu, Y; Duan, XQ; Chen, YT; Yang, L; Tang, XQ; Zhang, HB; Xiao, Q; Wang, L; Liu, L; Luo, XH

Luo, XH (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Hematol, Youyi Rd 1, Chongqing 400016, Peoples R China.

JOURNAL OF MEDICAL VIROLOGY, 2023; 95 (2):

Abstract

Patterns of hepatitis B virus reactivation (HBV-R) in HBsAg (-)/HBcAb (+) patients with B-cell non-Hodgkin lymphoma (NHL) receiving rituximab based im......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索